SDZXF Stock Chart & Stats
$79.65
$5.32(6.94%)
At close: 4:00 PM EDT
$79.65
$5.32(6.94%)
Day’s Range― - ―
52-Week Range$54.95 - $94.55
Previous CloseN/A
Volume112.00
Average Volume (3M)65.00
Market Cap
$36.69B
Enterprise Value$41.20B
Total Cash (Recent Filing)$1.74B
Total Debt (Recent Filing)$5.68B
Price to Earnings (P/E)38.2
Beta0.70
Next Earnings
Aug 05, 2026EPS Estimate
1.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.13
Shares Outstanding440,000,000
10 Day Avg. Volume115
30 Day Avg. Volume65
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)3.35
Price to Sales (P/S)2.82
P/FCF Ratio38.83
Enterprise Value/Market Cap1.12
Enterprise Value/Revenue3.69
Enterprise Value/Gross Profit7.82
Enterprise Value/Ebitda22.29
Forecast
1Y Price Target
$94.07Price Target Upside18.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)5.05
Revenue Forecast (FY)$14.99B
Bulls Say, Bears Say
Bulls Say
Revenue & Profitability ReboundA ~25% revenue increase and net margin recovery to ~8% in 2025 indicate the company regained pricing and volume traction after prior weakness. This kind of operational rebound signals sustainable revenue drivers and improved operating leverage from core generics and biosimilars, supporting multi‑period cash generation and investor visibility.
Consistently Strong Gross MarginsStable gross margins near 46–48% point to durable unit economics from low-cost manufacturing and product mix advantages in off‑patent medicines and biosimilars. Reliable gross margins help buffer price pressure in generics, supporting long‑term profitability even if top‑line growth cycles through tender and reimbursement dynamics.
Material Cash Flow Recovery In 2025A rebound to ~€1.6B operating cash flow and ~€0.81B free cash flow improves the firm's ability to fund operations, invest in capacity, pay down debt or sustain payouts. Strong cash generation after prior weakness demonstrates improved conversion of earnings to cash, enhancing medium‑term financial flexibility and resilience.
Bears Say
Earnings And FCF VolatilityLarge year‑to‑year swings in free cash flow and earnings highlight sensitivity to working capital, tender timing and investment cycles common in generics. This volatility makes forecasting cash available for reinvestment or debt reduction harder, increasing operating and financing risk over the next several quarters.
Rising Absolute Debt LevelsAlthough leverage is moderate, rising absolute debt from 2023–2025 raises interest and refinancing exposure. Higher debt can constrain capital allocation for R&D, capacity or M&A, and reduces flexibility to absorb future margin or revenue shocks, heightening balance‑sheet risk if cash generation weakens.
Historic Data Outlier Reduces Trend ConfidenceAn extreme 2022 outlier in debt and ROE undermines multi‑year comparability and trend analysis. This weakens confidence in projecting near‑term fundamentals, complicates benchmarking and elevates model risk for analysts and creditors relying on consistent historical metrics over the next 2–6 months.
Sandoz Group Ltd News
SDZXF FAQ
What was Sandoz Group Ltd’s price range in the past 12 months?
Sandoz Group Ltd lowest stock price was $54.95 and its highest was $94.55 in the past 12 months.
What is Sandoz Group Ltd’s market cap?
Sandoz Group Ltd’s market cap is $36.69B.
When is Sandoz Group Ltd’s upcoming earnings report date?
Sandoz Group Ltd’s upcoming earnings report date is Aug 05, 2026 which is in 3 days.
How were Sandoz Group Ltd’s earnings last quarter?
Sandoz Group Ltd released its earnings results on Feb 25, 2026. The company reported $2.025 earnings per share for the quarter, beating the consensus estimate of $1.73 by $0.295.
Is Sandoz Group Ltd overvalued?
According to Wall Street analysts Sandoz Group Ltd’s price is currently Undervalued.
Does Sandoz Group Ltd pay dividends?
Sandoz Group Ltd does not currently pay dividends.
What is Sandoz Group Ltd’s EPS estimate?
Sandoz Group Ltd’s EPS estimate is 1.79.
How many shares outstanding does Sandoz Group Ltd have?
Sandoz Group Ltd has 440,000,000 shares outstanding.
What happened to Sandoz Group Ltd’s price movement after its last earnings report?
Sandoz Group Ltd reported an EPS of $2.025 in its last earnings report, beating expectations of $1.73. Following the earnings report the stock price went up 14.329%.
Which hedge fund is a major shareholder of Sandoz Group Ltd?
Currently, no hedge funds are holding shares in SDZXF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sandoz Group Ltd
Operating globally, Sandoz Group AG specializes in the development, production, and distribution of generic medications and biosimilar products. The company's portfolio includes the creation and sale of finished dosage forms for small molecule pharmaceuticals, often supplied to other entities. Sandoz is also a significant player in the biotechnology sector, providing protein-based products such as biosimilars and offering specialized manufacturing services within this field. Furthermore, it supplies anti-infective products, including active pharmaceutical ingredients (APIs) and intermediates, with a strong emphasis on antibiotics. Established in 1886, Sandoz maintains its headquarters in Rotkreuz, Switzerland.
SDZXF Stock 12 Month Forecast
Average Price Target
$94.07
▲(18.11% Upside)
Technical Analysis
Ownership Overview
―
Insiders
8.70% Mutual Funds
<0.01% Other Institutional Investors
77.03% Public Companies and
Individual Investors